Mei Chang Yu

US Patent:

20080045499, Feb 21, 2008

Filed:

Feb 6, 2007

Appl. No.:

11/671926

Inventors:

Byron Zhao - Sugar Land TX, US
Mei Yu - San Francisco CA, US
Guriqbal Basi - Palo Alto CA, US

International Classification:

A61K 31/18
A61K 31/55
A61P 25/28
C07C 311/16
C07D 223/10
C07D 401/12
C07K 14/00
C07K 16/00
C12Q 1/02

US Classification:

514212030, 435029000, 514212040, 514604000, 514789000, 530324000, 530387900, 530389100, 540522000, 540524000, 540527000, 564092000

Abstract:

The invention provides methods for determining whether an agent preferentially inhibits Presenilin-1-comprised γ-secretase relative to Presenilin-2-comprised γ-secretase. The invention also provides agents that preferentially inhibit Presenilin-1-comprised γ-secretase relative to Presenilin-2-comprised γ-secretase, pharmaceutical compositions comprising such compounds, and methods of treating Alzheimer's disease using such compounds. The invention also discloses that the N-terminal domain of presenilin-1 and -2 determines the difference in the production of Aβ by PS1-comprised and PS2-comprised gamma secretases. This finding identified the structural determinant for the observed difference in the production of Aβ by PS1-comprised and PS2-comprised gamma secretases. Such structural determinant was not identified before. This invention also provides a method for determining whether an agent specifically binds the N terminus of PS1. The invention further provides for methods of treatment of Alzheimer's Disease by administration of an effective dose of an agent which specifically binds PS1, thereby inhibiting PS1 activity.

US Patent:

20130052633, Feb 28, 2013

Filed:

Jul 5, 2012

Appl. No.:

13/542551

Inventors:

Guofeng Cheng - Foster City CA, US
Hongmei Mo - Palo Alto CA, US
Simin Xu - Palo Alto CA, US
Mei Yu - San Francisco CA, US
Amoreena Corsa - San Francisco CA, US

Assignee:

Gilead Sciences, Inc. - San Francisco CA

International Classification:

C12N 15/63
C12Q 1/70
C07K 14/18
C07K 16/10
C12N 15/40
C12N 5/09

US Classification:

435 5, 4353201, 536 2372, 435370, 530350, 5303894

Abstract:

Replicons of genotype 3 of hepatitis C virus (HCV) are provided. These replicons contains adaptive mutations giving rise to the HCV's capability to replicate in vitro. Methods of preparing genotype 3 replicons and methods of using these replicons to screen antiviral agents are also provided.

US Patent:

20060246037, Nov 2, 2006

Filed:

Jul 30, 2004

Appl. No.:

10/575457

Inventors:

Bryon Zhao - Millbrae CA, US
Mei Yu - San Francisco CA, US

International Classification:

A61K 48/00
A61K 31/045

US Classification:

424093200, 514044000, 514738000

Abstract:

The present invention relates to methods for preventing cell death in a subject and the application of these methods for treating neurodegenerative diseases, such as Parkinson's disease, Alzheimer's disease, etc. In one embodiment of the invention, a method for preventing cell death may comprise effecting overexpression of an active form of ATF6 in the cell.

US Patent:

20180042905, Feb 15, 2018

Filed:

Aug 29, 2017

Appl. No.:

15/689985

Inventors:

- Foster City CA, US
Todd Appleby - San Francisco CA, US
Gabriel Birkus - San Francisco CA, US
Guofeng Cheng - Foster City CA, US
David Dornan - Burlingame CA, US
Tetsuya Kobayashi - Pleasanton CA, US
Christopher Charles Mello - Sunnyvale CA, US
Uli Schmitz - Foster City CA, US
Madeleine Willkom - Foster City CA, US
Mei Yu - Foster City CA, US

International Classification:

A61K 31/44
A61K 45/06

Abstract:

The present invention relates to novel methods of treating Hepatitis B Virus by administering a KDM5 inhibitor.

US Patent:

20160303095, Oct 20, 2016

Filed:

Apr 13, 2016

Appl. No.:

15/098112

Inventors:

- Foster City CA, US
Todd Appleby - San Francisco CA, US
Gabriel Birkus - Dublin CA, US
Guofeng Cheng - Foster City CA, US
David Dornan - Burlingame CA, US
Tetsuya Kobayashi - Pleasanton CA, US
Christopher Charles Mello - Sunnyvale CA, US
Uli Schmitz - Foster City CA, US
Madeleine Willkom - Foster City CA, US
Mei Yu - Foster City CA, US

International Classification:

A61K 31/44
A61K 45/06

Abstract:

The present invention relates to novel methods of treating Hepatitis B Virus by administering a KDM5 inhibitor.

US Patent:

20150058752, Feb 26, 2015

Filed:

Sep 19, 2013

Appl. No.:

14/032064

Inventors:

Ingrid Bernaudin - Palo Alto CA, US
Michael Dandan - San Mateo CA, US
Steve Zyszkiewicz - San Bruno CA, US
Frank Wang - Santa Clara CA, US
Mei Yu - Palo Alto CA, US
Vidya Viswanath - San Jose CA, US

Assignee:

SUCCESSFACTORS, INC. - South San Francisco US

International Classification:

H04L 29/06
G06F 3/0488
G06F 3/0482

US Classification:

715753

Abstract:

In one embodiment, an improved computer based daily task tool is provided that interfaces with backend systems to leverage the stored information and/or processing capabilities of backend systems to provide better information and more effective task tool functionality.

US Patent:

20140337638, Nov 13, 2014

Filed:

May 10, 2013

Appl. No.:

13/892048

Inventors:

- South San Francisco CA, US
Mei Yu - Palo Alto CA, US

Assignee:

SUCCESSFACTORS - South San Francisco CA

International Classification:

G06F 21/60

US Classification:

713189

Abstract:

In one embodiment the present invention includes a computer-implemented method for a mobile device. An application security status is detected. When the application security status is active an application passcode is required to access functionality of a mobile application operating on the mobile device. A first encryption of data associated with the mobile application is performed, where the first encryption uses a first encryption key when the application security status is active, and the first encryption uses a second encryption key when the application security status is not active. A mobile device passcode status is detected. When the mobile device passcode status is active a mobile device passcode is required to access functionality of the mobile computing device. A second encryption of the data is performed when the mobile device passcode status is active, where the second encryption uses a third encryption key.

US Patent:

20140134604, May 15, 2014

Filed:

Nov 6, 2013

Appl. No.:

14/073488

Inventors:

- Foster City CA, US
Betty Peng - London, GB
Mei Yu - San Francisco CA, US

International Classification:

C12Q 1/70
C07K 16/10
C07K 14/005

US Classification:

435 5, 536 2372, 435366, 530350, 5303894, 536 2433, 536 2432, 536 253

Abstract:

Replicons of genotype 6 hepatitis C virus (HCV) are provided. These replicons contain adaptive mutations giving rise to the HCV's capability to replicate in vitro. Methods of preparing genotype 6 replicons and methods of using these replicons to screen antiviral agents are also provided.